A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Overview

Información sobre este estudio

The purpose of this study is to determine if treatment with androgen deprivation therapy (ADT) plus apalutamide before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to ADT plus placebo.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria: 

  • Histologically confirmed adenocarcinoma of the prostate.
  • Candidate for radical prostatectomy with lymph node dissection as per the investigator.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Contraceptive (birth control) use by men (or female partners of men enrolled in the study who are of childbearing potential or are pregnant) should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies.
  • Able to receive androgen deprivation therapy (ADT) for up to 1 year, per the investigator's assessment.
  • Participants are considered eligible only if the central radiological review confirms clinical stage M0.

Exclusion Criteria: 

  • Distant metastasis (clinical stage M1).
  • Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion.
  • Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review.
  • Prior treatment with antiandrogen.
  • History of pelvic radiation for prostate cancer.
  • Use of any investigational agent ≤ 4 weeks prior to randomization or any therapeutic procedure for prostate cancer at any time.
  • Major surgery ≤ 4 weeks prior to randomization.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Winston Tan, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20473400

Mayo Clinic Footer